Chronic Heart Failure With Reduced Ejection Fraction
Conditions
Keywords
Heart Failure
Brief summary
The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.
Interventions
DRUGLY3461767
Administered SC.
DRUGPlacebo
Administered SC.
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential * Have a body mass index (BMI) of \</= 45.0 kilograms per square meter (kg/m²) * Have chronic stable heart failure (New York Heart Association (NYHA) classification II and III) on guideline directed heart failure therapy for at least 6 months prior to enrolment * Have not changed optimal guideline directed therapy in the last 1 month prior to screening, If treated with oral diuretics, dose must be stable for at least 2 weeks prior to screening * Have Left Ventricular Ejection Fraction (LVEF) \< 40% * Have a record of N-terminal pro b-type natriuretic peptide (NT-ProBNP) ≥ 200 picograms per millilitre (pg/mL) or a BNP value of \>/= 60 pg/mL within the past 12 months prior to screening
Exclusion criteria
* Have myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke in the last 90 days prior to screening * Have acute decompensated heart failure requiring IV diuretics within 12 weeks prior to screening * Have cardiac amyloidosis, accumulation diseases (e.g., haemochromatosis, Fabry disease), muscular dystrophies, hypertrophic cardiomyopathy, pericardial constriction, or complex congenital heart disease. * Have any moderate-to-severe stenosis of the mitral and/or aortic valve or moderate-to severe or greater mitral and/or aortic regurgitation. * Have a history or presence of hepatic, pancreatic, or biliary tract disorders * Have a history of malignancy or active malignancy at screening. * Have not had age-appropriate cancer screening as recommended by the American Cancer Society and per medical judgment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Baseline through Day 90 | A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK: Maximum Concentration (Cmax) of LY3461767 | Predose up to 48 hours post end of infusion | PK: Cmax of LY3461767 |
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3461767 | Predose up to 48 hours post end of infusion | PK: AUC of LY3461767 |
Countries
Japan, United States
Outcome results
None listed